lilly retatrutide trial A new clinical from Eli and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes VisualAbstract: Retatrutide reduces body weight

As Novo Nordisk works to defend its dominant market position, Structure Therapeutics represents a potential disruptor aiming to capture future share with innovative treatments, making this an intriguing matchup between an established giant and an emerging contender

[DOI] [PMC free article] [PubMed] [Google Scholar] 109.Muller DRP, et al

All bases covered

Structural characterization and hypoglycemic effect via stimulating glucagon-like peptide-1 secretion of two polysaccharides from Dendrobium officinale

The STEP 1 study looked at how Wegovy works in people with a BMI of 27 or higher

Wegovy, as an injection, is FDA approved to: Reduce excess body weight and maintain long-term weight reduction in: Adults with obesity and adolescents ages 12 years and older with obesity Adults with overweight plus at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol Treat a serious type of fatty liver disease called noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver scarring (stage F2 to F3 fibrosis) Lower the risk of major cardiovascular problems (such as heart attack, stroke, and heart-related death) in adults with established cardiovascular disease and obesity or overweight Contrave is FDA approved to: Reduce excess body weight and maintain long-term weight reduction in: Adults with obesity, defined as a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher (overweight) plus at least one weight-related medical condition To recap, heres an at-a-glance comparison of FDA-approved uses for Wegovy vs